Oncolytics Biotech Statistics
Share Statistics
Oncolytics Biotech has 77.07M shares outstanding. The number of shares has increased by 4.89% in one year.
| Shares Outstanding | 77.07M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.49% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 75.99M |
| Failed to Deliver (FTD) Shares | 10.88K |
| FTD / Avg. Volume | 2.17% |
Short Selling Information
The latest short interest is 2.81M, so 3.65% of the outstanding shares have been sold short.
| Short Interest | 2.81M |
| Short % of Shares Out | 3.65% |
| Short % of Float | 3.8% |
| Short Ratio (days to cover) | 3.51 |
Valuation Ratios
The PE ratio is -4.26 and the forward PE ratio is -3.73.
| PE Ratio | -4.26 |
| Forward PE | -3.73 |
| PS Ratio | 0 |
| Forward PS | 64.4 |
| PB Ratio | 4.29 |
| P/FCF Ratio | -4.15 |
| PEG Ratio | n/a |
Enterprise Valuation
Oncolytics Biotech Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 9.01, with a Debt / Equity ratio of 0.
| Current Ratio | 9.01 |
| Quick Ratio | 9.01 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.01% and return on capital (ROIC) is -121.17%.
| Return on Equity (ROE) | -1.01% |
| Return on Assets (ROA) | -0.71% |
| Return on Capital (ROIC) | -121.17% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -956.97K |
| Employee Count | 29 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 97.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -40% in the last 52 weeks. The beta is 1.51, so Oncolytics Biotech 's price volatility has been higher than the market average.
| Beta | 1.51 |
| 52-Week Price Change | -40% |
| 50-Day Moving Average | 1.08 |
| 200-Day Moving Average | 1.04 |
| Relative Strength Index (RSI) | 27.9 |
| Average Volume (20 Days) | 501.57K |
Income Statement
In the last 12 months, Oncolytics Biotech had revenue of $0 and earned -$27.75M in profits. Earnings per share was $-0.41.
| Revenue | 0 |
| Gross Profit | -403.00K |
| Operating Income | -33.79M |
| Net Income | -27.75M |
| EBITDA | -33.71M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.41 |
Balance Sheet
The company has $34.91M in cash and $423.00K in debt, giving a net cash position of $34.49M.
| Cash & Cash Equivalents | 34.91M |
| Total Debt | 423.00K |
| Net Cash | 34.49M |
| Retained Earnings | -446.00M |
| Total Assets | 24.26M |
| Working Capital | 15.25M |
Cash Flow
In the last 12 months, operating cash flow was -$28.45M and capital expenditures -$8.00K, giving a free cash flow of -$28.46M.
| Operating Cash Flow | -28.45M |
| Capital Expenditures | -8.00K |
| Free Cash Flow | -28.46M |
| FCF Per Share | -0.42 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ONCY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -50.62% |
| FCF Yield | -45.38% |
Analyst Forecast
The average price target for ONCY is $4, which is 393.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 393.8% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on May 25, 2018. It was a backward split with a ratio of 2:19.
| Last Split Date | May 25, 2018 |
| Split Type | backward |
| Split Ratio | 2:19 |
Scores
| Altman Z-Score | -28.62 |
| Piotroski F-Score | 1 |